Alex Keeton Named Head Of The Biosimilars Council, Senior Vice President Of Policy

Brings extensive health insurance and biotech experience

The Association for Accessible Medicines today welcomes Alex Keeton as the Executive Director of the Biosimilars Council and Senior Vice President of Policy for AAM. Keeton was most recently Vice President of Pharmacy Care Services at UnitedHealth Group and previously served in senior roles at the Biotechnology Innovation Organization and America’s Health Insurance Plans.

“Alex brings a wealth of experience to the Biosimilars Council and AAM including UnitedHealth, BIO, and AHIP,” said John Murphy III, President and CEO of AAM. “We are excited to welcome Alex to the team as we work to increase access and approvals for lower-cost generic and biosimilar medicines. Our industry is facing critical challenges, and we are focused on common-sense reforms that will benefit patients and the entire health care ecosystem.”

Alex Keeton will serve as Executive Director of the Biosimilars Council and Senior Vice President of Policy at the Association for Accessible Medicines where he will lead all aspects of biosimilars advocacy, policy, and outreach as well as AAM’s policy development and issues management to improve overall market sustainability and increase access to affordable generic and biosimilar medicines.

“It is an honor to lead the Biosimilars Council, and I am excited to join the team as we work with our member companies to expand access to generic and biosimilar medicines and work to build a more sustainable market for these life savings medicines,” said Keeton. “Biosimilars are an exciting and fast-growing segment that treat a host of conditions in innovative ways and bring significant savings and more choices for American patients. It is important we remove unnecessary regulatory obstacles that slow down biosimilar development and deployment.”

About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.

About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. For more information, visit www.biosimilarscouncil.org.